Address: P.O. Box 220 Five Dock NSW 2046 ,Australia
Tel: +61-2-9719 2800
Web: http://www.datapharmaustralia.com/
Datapharm Australia Pty Ltd is an Australian contract research organisation (CRO) and data management organisation (DMO) established in 1987. Consistent growth has met the demands of the increasing number of clinical trials in Australia . Datapharm Australia is actively involved in providing contract research services for local and international clinical trials, “big pharma” and “biotech”. Recently over 300 studies have been completed in 40 therapeutic areas with over 50 clients.
Datapharm Australia continues to develop global links enabling participation in international studies. Services include clinical study management, monitoring, data management, statistical analysis and report writing, training, pharmacovigilance, audits and supplying contract staff to assist our clients.
Datapharm Australia is well known in the industry for its role in managing clinical trials and for the niche data management services that it offers. This includes an emphasis on technology applications for clinical trials, programming and a strong statistics team to design studies and perform the statistical analysis. Datapharm Australia has forged strong relationships with the trial sponsors and investigators. The Datapharm Australia team is known for its friendly and professional communications, its years of experience and expertise in research, having a passion for the science and for providing quality solutions to support the projects.
Niche data management
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
See our Cookie Privacy Policy Here
